Bayer and Regeneron's hard-charging eye drug has traded its way to another victory. It won a recommendation from the U.K.'s cost-effectiveness watchdogs, on the strength of a pricing discount. Previously rejected as too expensive, Eylea is now in line for routine use by Britain's National Health Service.
Regeneron Pharmaceuticals is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years.
Allergan has slammed the brakes on two planned late-stage studies of a pair of key therapeutics in its pipeline, saying that investigators have to go back to the mid-stage drawing board in order to see whether their drugs work as hoped or whether a new formulation can salvage their efforts.
How much is a wildly successful drug worth? For Regeneron's top executives, the answer is $140 million. With its vision-loss drug beating all sales expectations for its first year on the market, the company's 5 highest-paid managers won $140,695,118 in 2012 compensation.
Baxter International has picked up the former Genmab antibody plant near Minneapolis for a small sum and will now invest about $300 million to get it ready for its own use.
Regeneron Pharmaceuticals has rolled out plans to add about 400 new workers to its fast-growing staff after it builds two new facilities, adding 300,000 square feet of lab and office space to its sprawling campus in New York state.
Analysts at GlobalData took a quarterly snapshot of the R&D expenses for a big batch of mid-cap biotechs and concluded that rising research costs were eroding corporate profitability. And they pinned the blame squarely on the pricey hunt for new cancer drugs.
A duo of new earnings announcements from smaller drugmakers offers a microcosmic view of the Big Pharma results we've seen so far. Generic competition hurts, new drugs need to fill the gap--and a successful drug launch is a thing to behold.
Now that the mega-mergers are completed, with a notoriously mixed record of success, and $1 billion to $3 billion bolt-ons have become all the rage at Big Pharma, things have grown rather quiet on the biopharma front. But some analysts are clearly expecting AstraZeneca to step up with a major league deal.
Just what does Sanofi ($SNY) have planned with Regeneron ($REGN)? The two companies raised eyebrows this morning with the announcement that Sanofi would be snapping up enough Regeneron stock to surpass the $500 million antitrust-notification threshold.